Document Detail


Effectiveness of infliximab in treating selected patients with sarcoidosis.
MedLine Citation:
PMID:  16935484     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To assess the effectiveness of infliximab (Remicade) in the treatment of patients with sarcoidosis who either do not respond to corticosteroids and other conventional drugs or develop unacceptable side effects to these drugs. DESIGN: A clinical, non-randomized, off-label study. SETTING: Sarcoidosis clinic at a university teaching hospital. PATIENTS: Twelve biopsy-proven sarcoidosis patients, nine women and three men ranging from 45 to 70 years of age with chronic multisystem sarcoidosis refractory to corticosteroids or alternative treatment. INTERVENTION: Infliximab was infused at a dedicated ambulatory infusion center. The initial dose was 3mg/kg body weight and subsequent doses were given at weeks 2, 4, 6, 10, and 14. All patients received at least six infusions. RESULTS: All 12 patients improved significantly. One patient had a mild allergic drug reaction that responded to antihistamine. One patient, after 3 months of stopping infliximab treatment, died of a ruptured blood vessel in the abdomen. At autopsy a plasma cell dyscrasia was found. CONCLUSION: Infliximab is safe and effective in treating those patients with multisystem sarcoidosis who are either refractory or develop side effects to a standard regimen of corticosteroids and immunosuppressive agents.
Authors:
Samer Saleh; Shahriar Ghodsian; Violeta Yakimova; John Henderson; Om P Sharma
Related Documents :
10369544 - Pemphigus in kuwait.
18639144 - Nitrous oxide-induced vitamin b(12) deficiency.
19825284 - Corticosteroids (dexamethasone versus intravenous methylprednisolone) in patients with ...
2085334 - Long-term multicentric study with azelastine in patients with intrinsic asthma.
11603594 - Differences in heart valve procedures between north american and european centers: a re...
7215824 - A comparison of total hip replacement in patients aged 69 years or less and 70 years or...
Publication Detail:
Type:  Case Reports; Clinical Trial; Journal Article     Date:  2006-08-28
Journal Detail:
Title:  Respiratory medicine     Volume:  100     ISSN:  0954-6111     ISO Abbreviation:  Respir Med     Publication Date:  2006 Nov 
Date Detail:
Created Date:  2006-10-10     Completed Date:  2007-01-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8908438     Medline TA:  Respir Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  2053-9     Citation Subset:  IM    
Affiliation:
Department of Medicine, Pulmonary & Critical Care Division, University of Southern California, 1200N, State St., GNH 11900, Los Angeles, CA 90033, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Anti-Inflammatory Agents / adverse effects,  therapeutic use*
Antibodies, Monoclonal / adverse effects,  therapeutic use*
Chronic Disease
Female
Humans
Male
Middle Aged
Sarcoidosis / drug therapy*,  pathology
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Antibodies, Monoclonal; 0/infliximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Modulation of phosphoinositide-protein kinase C signal transduction by omega-3 fatty acids: implicat...
Next Document:  Design of highly efficient receptor sites by combination of cyclodextrin units and molecular cavity ...